1. Home
  2. SCYX vs NDLS Comparison

SCYX vs NDLS Comparison

Compare SCYX & NDLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • NDLS
  • Stock Information
  • Founded
  • SCYX 1999
  • NDLS 1995
  • Country
  • SCYX United States
  • NDLS United States
  • Employees
  • SCYX N/A
  • NDLS N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • NDLS Restaurants
  • Sector
  • SCYX Health Care
  • NDLS Consumer Discretionary
  • Exchange
  • SCYX Nasdaq
  • NDLS Nasdaq
  • Market Cap
  • SCYX 32.3M
  • NDLS 29.8M
  • IPO Year
  • SCYX 2014
  • NDLS 2013
  • Fundamental
  • Price
  • SCYX $0.75
  • NDLS $0.62
  • Analyst Decision
  • SCYX
  • NDLS Buy
  • Analyst Count
  • SCYX 0
  • NDLS 2
  • Target Price
  • SCYX N/A
  • NDLS $3.00
  • AVG Volume (30 Days)
  • SCYX 665.7K
  • NDLS 124.1K
  • Earning Date
  • SCYX 11-05-2025
  • NDLS 11-05-2025
  • Dividend Yield
  • SCYX N/A
  • NDLS N/A
  • EPS Growth
  • SCYX N/A
  • NDLS N/A
  • EPS
  • SCYX N/A
  • NDLS N/A
  • Revenue
  • SCYX $3,257,000.00
  • NDLS $494,752,000.00
  • Revenue This Year
  • SCYX $20.23
  • NDLS $1.19
  • Revenue Next Year
  • SCYX $933.90
  • NDLS N/A
  • P/E Ratio
  • SCYX N/A
  • NDLS N/A
  • Revenue Growth
  • SCYX N/A
  • NDLS N/A
  • 52 Week Low
  • SCYX $0.66
  • NDLS $0.55
  • 52 Week High
  • SCYX $1.62
  • NDLS $1.74
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 37.17
  • NDLS 41.44
  • Support Level
  • SCYX $0.73
  • NDLS $0.61
  • Resistance Level
  • SCYX $0.91
  • NDLS $0.69
  • Average True Range (ATR)
  • SCYX 0.07
  • NDLS 0.04
  • MACD
  • SCYX -0.01
  • NDLS 0.01
  • Stochastic Oscillator
  • SCYX 13.77
  • NDLS 16.09

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.

Share on Social Networks: